Meeting
2023 ASCO Genitourinary Cancers Symposium
Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma (ODYSSEY RCC).
Authors
Michael Roger Harrison
Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC
Michael Roger Harrison , Nrupen Anjan Bhavsar , Yasser Ged , Ajjai Shivaram Alva , Yousef Zakharia , Risa Liang Wong , Brian Addis Costello , Benjamin L. Maughan , Paul Monk III, Shreya Sinha , Deepak Kilari , Sarah Jabusch , Tian Zhang , Charles D. Scales Jr., Daniel J. George , Elizabeth Marie Wulff-Burchfield
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Clinical Trial Registration Number
NCT04919122
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS739)
DOI
10.1200/JCO.2023.41.6_suppl.TPS739
Abstract #
TPS739
Poster Bd #
M17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving dual immune checkpoint inhibitor (ICI-ICI) regimens or immune checkpoint inhibitor and tyrosine kinase inhibitor (ICI-TKI) combinations as first-line therapy: A British Columbia (BC) population-based analysis.
First Author: Antoine Morin Coulombe
Poster
2020 ASCO Virtual Scientific Program
A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.
First Author: Patrick Cheung
Poster
2024 ASCO Genitourinary Cancers Symposium
Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data.
First Author: Daniel M. Geynisman
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
First Author: Connor Wells